cannabis sole source announcement.pdf

Synopsis: Notice of Intent to Award a Sole Source Contract

Announcement Number: FDASS1263544

Project Title: CANNABIS-DERIVED PRODUCT DATA AND RELATED SERVICES

The Food and Drug Administration (FDA) intends to negotiate on a sole source basis with S-3 Research LLC to provide services in support of the project “Cannabis-Derived Product Data and Related Services using the procedures in FAR Part 12.6.

Per a sources sought notice posted on SAM.gov on December 2, 2022 (FDA-SSN- 12022022) three contractors submitted responses to which only one of them (S-3 Research LLC) was determined to be the possible source for this requirement.

Additionally, the nature of this requirement is deemed urgent due to unusual and compelling circumstances. Following competitive procedures would result in unacceptable delays concerning this project.

The North American Industry Classification Code (NAICS) for this acquisition is 541715, Research and Development Physical, Engineering and Life Sciences (except for Nanotechnology and Biotechnology) with a business size standard of 1,000 employees.

This is not a solicitation for competitive quotes, nor one will be posted on SAM.gov website.

The determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. However, if any interested party believes that it can meet the requirements, and if an effort to comply with the requirements as outlined in FAR 5.102, a firm may request an electronic copy of the solicitation from the contracting officer, Howard S. Yablon, howard.yablon@fda.hhs.gov.

All electronic correspondence shall have the subject line read: Announcement Number: FDASS1263544.

All responsible sources may submit a Capability Statement and/or a proposal in accordance with the solicitation which may be considered by the Agency if received on or before 4:00 PM ET on Thursday February 2, 2023. The Capability mailto:howard.yablon@fda.hhs.gov

Statement must contain material in sufficient detail to allow the FDA to determine if the party can meet all of the requirements.